Is Amgen's FOURIER Enough For Physicians, Payers To Expand Repatha Use?
Detailed results presented at ACC show a reduction in risk of major adverse cardiovascular events, but perhaps not at the level hoped for by payers.
You may also be interested in...
Amgen’s R&D Group Focuses On Efficiency As Drug Cost Concerns Continue
Scrip spoke with R&D head David Reese about improving R&D timelines and success rates, including through the use of genomics and proteomics, as data readouts near for key drugs in big indications.
New CV Outcomes Study May Mean Big Boost For Amgen's Repatha Market
The addressable patient population in the US could increase by 4.5 million if new trial is successful.
New US Cholesterol Guidelines Hit PCSK9s Hard On Pricing, Value
Already outdated? The latest ACC/AHA guidelines say at mid-2018 list prices, PCSK9 injectables are of low value, but the costs have plummeted since then.